Analyst firms · UBS · JAZZ
UBS JAZZ price target and rating history
Jazz Pharmaceuticals plc (JAZZ) · Health Care
UBS rates Jazz Pharmaceuticals plc (JAZZ) Buy with a $307 price target, as of its latest action on May 19, 2026. It has published 5 rating actions on JAZZ since June 2022, including 2 upgrades and 2 downgrades. Across 8 firms with a JAZZ price target in the last 12 months, the median target is $273. UBS's $307 is 12% above that.
- Current rating
- Buy
- Price target
- $307
- Median target, all firms
- $273
- Actions on JAZZ
- 5
UBS price target on JAZZ
Every UBS rating on JAZZ
- May 19, 2026
- Nov 24, 2025
- Mar 7, 2025
- Nov 27, 2023
- Jun 14, 2022
How other firms rate JAZZ
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $325 | Sep 30, 2026 |
| Goldman Sachs | Buy | $337 | Sep 24, 2026 |
| Canaccord Genuity | Buy | $290 | Jul 17, 2026 |
| Truist Securities | Buy | $256 | Jun 9, 2026 |
| Bernstein | Mkt Perform | $229 | May 22, 2026 |
| UBS | Buy | $307 | May 19, 2026 |
| Raymond James | Outperform | $227 | Apr 10, 2026 |
| Barclays | Overweight | $224 | Feb 27, 2026 |
Questions about UBS and JAZZ
- What is UBS's price target for JAZZ?
- UBS's latest stated price target for Jazz Pharmaceuticals plc (JAZZ) is $307, from its action on May 19, 2026.
- What is UBS's rating on JAZZ?
- UBS rates JAZZ Buy, a bullish rating, as of May 19, 2026.
- When did UBS last change its view on JAZZ?
- On May 19, 2026, UBS upgrades to Buy from Neutral, price target $307.
- How does UBS's JAZZ target compare with other analysts?
- Across 8 firms with a JAZZ price target in the last 12 months, the median target is $273. UBS's $307 is 12% above that.
More JAZZ rating histories
All UBS ratingsJAZZ news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.